Novo Nordisk A/S (NYSE:NVO) Trading Down 4% – Time to Sell?

Novo Nordisk A/S (NYSE:NVO) was down 4% on Thursday . The stock traded as low as $46.29 and last traded at $46.5390. Approximately 43,090,467 shares changed hands during mid-day trading, an increase of 246% from the average daily volume of 12,442,310 shares. The stock had previously closed at $48.46.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on NVO. Rothschild Redb upgraded Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 16th. Jefferies Financial Group assumed coverage on Novo Nordisk A/S in a research report on Monday, October 27th. They issued an “underperform” rating on the stock. Morgan Stanley lowered shares of Novo Nordisk A/S from an “overweight” rating to an “underweight” rating and lowered their price objective for the stock from $59.00 to $47.00 in a research note on Monday, September 29th. BNP Paribas raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a report on Wednesday, August 13th. Finally, BNP Paribas Exane raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 target price on the stock in a research report on Wednesday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $59.20.

Novo Nordisk A/S Trading Down 1.9%

The business has a 50 day moving average of $55.32 and a two-hundred day moving average of $61.49. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. The firm has a market capitalization of $203.69 billion, a price-to-earnings ratio of 12.53, a P/E/G ratio of 2.33 and a beta of 0.65.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The business had revenue of $11.74 billion during the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S has set its FY 2025 guidance at EPS. Equities analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in NVO. Revolve Wealth Partners LLC boosted its position in Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after buying an additional 200 shares during the period. Bank of New York Mellon Corp boosted its position in Novo Nordisk A/S by 6.0% during the 1st quarter. Bank of New York Mellon Corp now owns 839,802 shares of the company’s stock valued at $58,316,000 after acquiring an additional 47,804 shares in the last quarter. Penserra Capital Management LLC raised its holdings in Novo Nordisk A/S by 29.7% in the first quarter. Penserra Capital Management LLC now owns 7,831 shares of the company’s stock worth $543,000 after purchasing an additional 1,794 shares in the last quarter. U.S. Capital Wealth Advisors LLC lifted its position in Novo Nordisk A/S by 26.6% during the 1st quarter. U.S. Capital Wealth Advisors LLC now owns 8,773 shares of the company’s stock valued at $609,000 after acquiring an additional 1,843 shares during the period. Finally, Linden Thomas Advisory Services LLC grew its stake in shares of Novo Nordisk A/S by 12.8% in the 1st quarter. Linden Thomas Advisory Services LLC now owns 4,011 shares of the company’s stock worth $279,000 after buying an additional 456 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.